Results 171 to 180 of about 3,819 (202)
Some of the next articles are maybe not open access.
Eluxadoline, Lesinurad, and Idarucizumab
Journal of the American Pharmacists Association, 2016Irritable bowel syndrome (IBS) is estimated to affect 10% to 15% of adults in the United States. Some patients with IBS experience diarrhea as the most common manifestation (IBS-D), and others experience constipation as the most commonmanifestation (IBS-C).
Daniel A, Hussar, Maggie, Gandhi
openaire +2 more sources
Reversal of Dabigatran with Idarucizumab
Expert Review of Cardiovascular Therapy, 2016The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R, Sodha, Frank W, Sellke
openaire +2 more sources
Idarucizumab: First Global Approval
Drugs, 2015Idarucizumab (Praxbind(®)) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific antidote to reverse the anticoagulant effect of the direct oral thrombin inhibitor dabigatran etexilate (Pradaxa(®)). Idarucizumab received its first global approval, in the USA, in October 2015 for use in adult patients treated
openaire +2 more sources
Idarucizumab: What Should We Know?
Current Drug Targets, 2018Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis.
Cortese F. +9 more
openaire +4 more sources
Incomplete dabigatran reversal with idarucizumab
Clinical Toxicology, 2017With increasing use of direct oral anticoagulants (DOACs), urgent reversal of these agents becomes a growing concern. Idarucizumab is a humanized monoclonal antibody fragment that specifically binds to dabigatran with higher affinity than thrombin, rapidly neutralizing its anticoagulant effect without increased risk of thrombosis.We describe two cases ...
Aaron P. Steele +2 more
openaire +2 more sources
Real-world experience with reversal of dabigatran by idarucizumab
Thrombosis Research, 2021Erik L. Grove +2 more
exaly